Document Type
Article
Publication Date
5-25-2025
Abstract
Background and Objectives
The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy and tolerability among patients. This study sought to investigate the relationship, if any, of single nucleotide polymorphisms (SNPs) and selected clinical parameters.
Methods
The study population, predominantly Caucasian males with a median age of 53.0 years [interquartile range 46.0–59.0], was assayed for genetic variations using an iPLEX ADME PGx Pro v1.0 Panel.
Results
Although several SNP relationships were found with both forms of tenofovir, many of the reported SNPs were displayed only in the comprehensive regimen grouping, making it difficult to distinguish between the two prodrug forms.
Conclusions
Being an exploratory study, the findings of this substudy serve as potential avenues for further research.
Recommended Citation
Murrell, D.E., Kennard, B.C., Bertoni, M.E. et al. An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate. Drugs R D (2025). https://doi.org/10.1007/s40268-025-00509-6
Copyright
The authors
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Included in
Immune System Diseases Commons, Medicinal and Pharmaceutical Chemistry Commons, Nucleic Acids, Nucleotides, and Nucleosides Commons, Other Pharmacy and Pharmaceutical Sciences Commons
Comments
This article was originally published in Drugs in R & D in 2025. https://doi.org/10.1007/s40268-025-00509-6